Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-09), Apex Biotechnology's 3-1 Month Momentum % is 11.69%.
The industry rank for Apex Biotechnology's 3-1 Month Momentum % or its related term are showing as below:
TPE:1733's 3-1 Month Momentum % is ranked better than 69.45% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: -0.56
vs TPE:1733: 11.69
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Apex Biotechnology 3-1 Month Momentum % Related Terms
TPE:1733 vs VRTX, REGN, MRNA: 3-1 Month Momentum % Comparison
For the Medical Devices subindustry, Apex Biotechnology's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apex Biotechnology 3-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Apex Biotechnology's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Apex Biotechnology's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apex Biotechnology (TPE:1733) has a 3-1 Month Momentum % of 11.69% as of Sep. 09, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Apex Biotechnology and its competitors. According to the industry distribution chart, Apex Biotechnology ranks #260 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 30.6%.
Is Apex Biotechnology's 3-1 Month Momentum % too high?
Apex Biotechnology's current 3-1 Month Momentum % is 11.69%. Based on the distribution chart, Apex Biotechnology ranks #260 out of 851 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Apex Biotechnology has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Apex Biotechnology's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Medical Devices & Instruments industry distribution chart, Apex Biotechnology ranks #260 out of 851 companies for 3-1 Month Momentum %. This puts Apex Biotechnology in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
A good 3-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Apex Biotechnology and its competitors. Apex Biotechnology's current 3-1 Month Momentum % is 11.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apex Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Apex Biotechnology (TPE:1733) is currently considered Fairly Valued. The stock's GF Value™ is NT$29.98, compared to a current price of NT$31.35 — trading 4.6% above its estimated fair value. The current 3-1 Month Momentum % is 11.69%. Apex Biotechnology's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Apex Biotechnology (TPE:1733), the current 3-1 Month Momentum % is 11.69% as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apex Biotechnology (TPE:1733) Overvalued in 2026?
Based on GuruFocus' analysis, Apex Biotechnology stock appears to be overvalued.
The current stock price of NT$31.35 is trading 4.6% above its estimated GF Value™ of NT$29.98.
GuruFocus considers Apex Biotechnology to be Fairly Valued.
Key valuation signals for TPE:1733:
3-1 Month Momentum %: 11.69%
GF Value™: NT$29.98 vs. price of NT$31.35 (4.6% above fair value)
No single metric tells the full story. See the TPE:1733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apex Biotechnology Corp is engaged in the research, development, production, manufacturing, and sale of biochemical testing instruments and proprietary test strips, as well as the import and export of products and components related to its core business. Its product offerings include diabetes testing kits, blood uric acid monitoring systems, blood lactate monitoring systems, blood haemoglobin monitoring systems, etc. The company generates maximum revenue from the sale of test strips, and the rest from testing meters, electrodes, and other products. Geographically, it derives maximum revenue from the USA, and the rest from Italy, Austria, Taiwan, China, and other markets.
80GF Score
Get the complete analysis for TPE:1733
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1733 has been successfully added to your 
